DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.
Summary for Tradename: OPTISON
Clinical Trials for: OPTISON
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
Status: Completed Condition: Echocardiography
Regadenoson Real Time Perfusion Imaging Trial-Optison
Status: Recruiting Condition: Coronary Artery Disease; Myocardial Perfusion Abnormalities
Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
Status: Completed Condition: Abdominal Neoplasms; Pelvic Neoplasms
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
Status: Completed Condition: Pulmonary Hypertension
Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
Status: Terminated Condition: Carotid Artery Disease
Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage
Status: Not yet recruiting Condition: Atrial Fibrillation
Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma
Status: Not yet recruiting Condition: Abdominal Trauma
Pre-operative Evaluation of Kidney & Pancreas Transplant Patients
Status: Active, not recruiting Condition: Kidney Transplantation; Pancreas Transplantation
Detection of Coronary Stenosis With Intravenous Microbubbles
Status: Withdrawn Condition: Coronary Stenosis; Carotid Stenosis; Myocardial Reperfusion
Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)
Status: Withdrawn Condition: Coronary Artery Disease
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Product||Substance||Delist_Flag||Patent Expiration||Exclusivity Expiration|
|INJECTABLE; INJECTION||020899||Dec 31, 1997||RX||Yes||<disabled>||<disabled>|
|INJECTABLE; INJECTION||020899||Dec 31, 1997||RX||Yes||5,529,766||<disabled>||<disabled>|
|INJECTABLE; INJECTION||020899||Dec 31, 1997||RX||Yes||6,723,303||Y||<disabled>||<disabled>|
|The preview shows a limited data set. Complete access is available with a Subscription|
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639`abc